title: Bevacizumab in advanced cancer, too much or too little?
authors.forename: A
authors.initials: A
authors.lastname: Jirillo
authors.forename: F
authors.initials: F
authors.lastname: Vascon
authors.forename: M
authors.initials: M
authors.lastname: Giacobbo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016527:Drug Costs; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab